Clinical trials: Squamous Cell Carcinoma of Cervix
Cervical Cancer, Vaginal Cancer
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with advanced…
- Trial name
- NCT00002562
- Testing
- paclitaxel
- Where
- 50 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gynecologic Oncology Group
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
- Trial name
- NCT06319963
- Testing
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Theravectys S.A.
Metastatic Colorectal Cancer, Metastatic Cervical Cancer
Safety of Effivia®, a Bevacizumab Biosimilar
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
- Trial name
- NCT06313268
- Testing
- Bevacizumab Biosimilar MB02
- Where
- 5 sites in Mexico
- Volunteers
- 83 people
- Sponsor
- Laboratorios Liomont
Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018
A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
This phase IIA trial studies the effect of a vaccine (PDS0101) when given together with chemotherapy and radiation therapy (chemoradiation) in treating patients with stage IB3-IVA cervical cancer.
- Conditions
- Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018
- Trial name
- NCT04580771
- Testing
- Cisplatin, Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Radiation Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer
Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as tirapazamine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098995
- Testing
- cisplatin, tirapazamine, brachytherapy
- Where
- 2 sites in Australia, Canada
- Volunteers
- 22 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Squamous Cell Lung Cancer, Vulvar Cancer
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic squamous cell carcinoma (localisations : head and…
- Conditions
- Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer, Cervix Cancer
- Trial name
- PEVOsq (NCT04357873)
- Testing
- pembrolizumab; vorinostat
- Where
- 14 sites in France
- Volunteers
- 112 people
- Sponsor
- UNICANCER
Cervical Cancer, Endometrial Cancer
Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery
RATIONALE: Specialized radiation therapy (RT), such as intensity-modulated radiation therapy (IMRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00331760
- Testing
- cisplatin, intensity-modulated radiation therapy
- Where
- 153 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Non Small Cell Lung Cancer, Cervical Cancer
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with…
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer
- Trial name
- NCT04925284
- Testing
- XB002, Nivolumab, Bevacizumab
- Where
- 95 sites in United States, Australia and 7 more
- Volunteers
- 269 people
- Sponsor
- Exelixis
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
This phase I trial is studying the side effects and best dose of gemcitabine when given together with radiation therapy and cisplatin in treating patients with cervical cancer that has not spread beyond the pelvis.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00068549
- Testing
- Gemcitabine Hydrochloride, Cisplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer, Cervical Cancer Metastatic
QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy
To explore the efficacy and safety of administrating QL1706 in patients with recurrent and/or metastatic cervical cancer who had developed resistance to prior PD-1/PD-L1 antibody therapies.
- Conditions
- Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent, Cervical Adenocarcinoma
- Trial name
- NCT07141186
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cervical Cancer
Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela
1. Hypothesis: If high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer worldwide, the genotypes associated with cervical cancer in Venezuela would be the same types found in other countries. 2.
- Trial name
- HPI (NCT00937547)
- Where
- 2 sites in Venezuela
- Volunteers
- 329 people
- Sponsor
- Instituto Oncologico Luis Razetti
Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer.
- Conditions
- Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma, Advanced Vaginal Adenocarcinoma
- Trial name
- NCT02595879
- Testing
- Biospecimen Collection, Brachytherapy, Cisplatin
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Breast Cancer
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without intratumoral poly-ICLC. A device called the Echopulse will be used for the FUSA therapy.
- Conditions
- Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer
- Trial name
- AM-003 (NCT04116320)
- Testing
- Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Craig L Slingluff, Jr
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
- Trial name
- NCT02921269
- Testing
- Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis
- Where
- 22 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Cervical Cancer
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002813
- Testing
- cisplatin, vinorelbine tartrate
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- Gynecologic Oncology Group
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Trial name
- NCT02140021
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study of NEO-201 in Solid Tumors Expansion Cohorts
The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
- Trial name
- NCT03476681
- Testing
- NEO-201 in combination with pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 121 people
- Sponsor
- Precision Biologics, Inc